104 related articles for article (PubMed ID: 29129599)
1. ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis.
Fuhriman JM; Winge MCG; Haberstock-Debic H; Funk JO; Bradshaw JM; Marinkovich MP
J Invest Dermatol; 2018 Apr; 138(4):864-871. PubMed ID: 29129599
[TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression.
Cho HS; Shin HM; Haberstock-Debic H; Xing Y; Owens TD; Funk JO; Hill RJ; Bradshaw JM; Berg LJ
J Immunol; 2015 Nov; 195(10):4822-31. PubMed ID: 26466958
[TBL] [Abstract][Full Text] [Related]
4. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
6. RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis.
Saito N; Honma M; Shibuya T; Iinuma S; Igawa S; Kishibe M; Ishida-Yamamoto A
J Dermatol Sci; 2018 Jul; 91(1):79-86. PubMed ID: 29661487
[TBL] [Abstract][Full Text] [Related]
7. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Lovato P; Norsgaard H; Tokura Y; Røpke MA
J Dermatol Sci; 2016 Mar; 81(3):153-64. PubMed ID: 26794805
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
[TBL] [Abstract][Full Text] [Related]
9. Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates.
Gomez-Rodriguez J; Kraus ZJ; Schwartzberg PL
FEBS J; 2011 Jun; 278(12):1980-9. PubMed ID: 21362139
[TBL] [Abstract][Full Text] [Related]
10. The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development.
Prince AL; Yin CC; Enos ME; Felices M; Berg LJ
Immunol Rev; 2009 Mar; 228(1):115-31. PubMed ID: 19290924
[TBL] [Abstract][Full Text] [Related]
11. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells.
Vollmer S; Menssen A; Trommler P; Schendel D; Prinz JC
Eur J Immunol; 1994 Oct; 24(10):2377-82. PubMed ID: 7925564
[TBL] [Abstract][Full Text] [Related]
12. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.
Van Belle AB; de Heusch M; Lemaire MM; Hendrickx E; Warnier G; Dunussi-Joannopoulos K; Fouser LA; Renauld JC; Dumoutier L
J Immunol; 2012 Jan; 188(1):462-9. PubMed ID: 22131335
[TBL] [Abstract][Full Text] [Related]
13. Mutation of Tec family kinases alters T helper cell differentiation.
Schaeffer EM; Yap GS; Lewis CM; Czar MJ; McVicar DW; Cheever AW; Sher A; Schwartzberg PL
Nat Immunol; 2001 Dec; 2(12):1183-8. PubMed ID: 11702066
[TBL] [Abstract][Full Text] [Related]
14. Xenotransplantation Model of Psoriasis.
Di Domizio J; Conrad C; Gilliet M
Methods Mol Biol; 2017; 1559():83-90. PubMed ID: 28063039
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
16. Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model.
Wang Y; Zhao J; Zhang L; Di T; Liu X; Lin Y; Zeng Z; Li P
Int J Clin Exp Pathol; 2015; 8(6):6665-73. PubMed ID: 26261548
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection.
He F; Yao H; Xiao Z; Han J; Zou J; Liu Z
Mol Immunol; 2014 May; 59(1):30-8. PubMed ID: 24462896
[TBL] [Abstract][Full Text] [Related]
18. Acetyl-11-keto-β-boswellic acid inhibits the secretion of cytokines by dendritic cells via the TLR7/8 pathway in an imiquimod-induced psoriasis mouse model and in vitro.
Wang MX; Zhao JX; Meng YJ; Di TT; Xu XL; Xie XJ; Lin Y; Zhang L; Wang N; Li P; Wang Y
Life Sci; 2018 Aug; 207():90-104. PubMed ID: 29859222
[TBL] [Abstract][Full Text] [Related]
19. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17.
Lin ZM; Ma M; Li H; Qi Q; Liu YT; Yan YX; Shen YF; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Pharmacol Res; 2018 Mar; 129():443-452. PubMed ID: 29155016
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD
Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
